BeiGene, Ltd. (BGNE) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Cambridge, MA, United States. वर्तमान CEO हैं John V. Oyler.
BGNE के पास है IPO तिथि 2016-02-03, 10,600 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $20.21B.
BeiGene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for cancer treatment globally. The company's commercial portfolio includes approved drugs such as BRUKINSA for mantle cell lymphoma, Tislelizumab for Hodgkin's lymphoma, and several other therapies for hematologic and solid tumors, complemented by a robust pipeline of clinical-stage candidates targeting various cancer types through innovative mechanisms including BTK inhibitors, PD-1/PD-L1 antibodies, kinase inhibitors, and specialized immunotherapies. BeiGene maintains strategic partnerships with leading pharmaceutical companies including Amgen, Novartis, and Bristol Myers Squibb to strengthen its research and commercialization capabilities. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company operates a comprehensive oncology platform serving patients worldwide.
